Details for Patent: 5,698,594

United States Patent 5,698,594: What the Claims Cover and How to Map the Landscape

What does US 5,698,594 claim, in plain scope terms?

US Patent 5,698,594 is directed to methods of treatment or prophylaxis using a defined mixed omega-3 fatty acid composition. The composition is characterized by (1) high omega-3 content, (2) a constrained EPA:DHA weight ratio, and (3) a required minor component of heneicosapentaenoic acid (HPA, 21:5 omega-3), with optional constraints on fatty acid profile (other omega-3s with C20-22), ester form (ethyl ester, free acid, salt), and dosing.

Core claim architecture

The claims cluster into two therapeutic buckets and then progressively narrow the formulation:

1. Hypertension in adults (Claims 1-11, with nested dependent limitations).
2. Multiple risk factors for cardiovascular disease (Claims 12-22, with nested dependent limitations).

Across both buckets, the composition is defined as “consist essentially of” a specific mixture of fatty acids (not a broad “fish oil” genus claim). That phrasing is pivotal: it signals the applicant aimed to preserve coverage for the specified omega-3 profile while still allowing limited additional components not materially affecting the specified fatty acid mix.

Shared chemical limitations present throughout

Every method claim in the set is built on the same composition constraints (directly or through dependency). The key constraints are:

• At least 80% by weight of the fatty acids is comprised of EPA and DHA combined.
• EPA:DHA weight ratio from 1:2 to 2:1.
• At least 1% by weight of the fatty acid mixture is heneicosapentaenoic acid (6,9,12,15,18-HPA, all-Z omega-3).
• The composition includes a pharmaceutically acceptable carrier (Claims 12-13 explicitly; Claim 1 implicitly via “pharmaceutical composition” language).

The claims also add optional profile and form limitations, including:

• Long-chain omega-3 fatty acids threshold (at least 85% long chain; Claims 2 and 14).
• EPA 40 to 60 wt% and DHA 25 to 45 wt% (Claims 3 and 15).
• Additional omega-3s with 20, 21, or 22 carbon atoms must be present above certain minimums (Claims 6, 17, 18).
• Esterified form, and specifically ethyl ester form (Claims 8-11, 19-20).
• Salt form (Claim 21).
• Free acid form (Claim 10, 22).

Daily dosing and administration form

For the cardiovascular risk-factor bucket, Claim 13 additionally requires:

• Oral administration
• Daily dosage of 1 to 10 grams of the mixture of fatty acids

Claim 5 is the hypertension analogue for oral dosing, and Claim 4 ties hypertension to the dosage regime language.

How do the hypertension claims narrow the formulation?

Claim set: hypertension (Claims 1-11)

Claim 1 is the independent method claim: daily treatment or prophylaxis of hypertension in an adult human, using a pharmaceutical composition whose active ingredients consist essentially of the specified fatty acid mixture with:

• ≥80 wt% EPA + DHA
• EPA:DHA from 1:2 to 2:1
• ≥1 wt% HPA (all-Z omega-3)

Claim 2: further requires ≥85 wt% long-chain omega-3 fatty acids in the mixture.

Claim 3: fixes the internal EPA/DHA range to:

• EPA 40 to 60 wt%
• DHA 25 to 45 wt%

Claim 4: reasserts EPA:DHA ratio as 1:1 to 2:1.

Claim 5: oral administration.

Claim 6: requires that ≥3 wt% of the mixture is omega-3s other than EPA/DHA with 20, 21, or 22 carbon atoms.

Claim 7: requires ≥90 wt% long-chain, polyunsaturated, omega-3 fatty acids.

Claims 8-10: select fatty acid presentation:

• Claim 8: esterified form
• Claim 9: ethyl ester form
• Claim 10: free acid form

Claim 11: tightens both the quantity and form together:

• ≥85 wt% of fatty acid content is EPA + DHA
• fatty acids are in ethyl ester form

Compression of the hypertension scope into a single “design space” table

How do the cardiovascular risk-factor claims expand and tighten?

Claim set: multiple risk factors for cardiovascular diseases (Claims 12-22)

Claim 12 is a cardiovascular-risk independent method claim, framed more broadly than the hypertension bucket but with a composition definition that is substantially similar to Claim 1. It requires:

• At least 80 wt% of the composition is omega-3 fatty acids
• At least 80 wt% of the total fatty acid content is EPA + DHA in EPA:DHA = 1:2 to 2:1
• At least 1 wt% of total fatty acids is HPA
• Fatty acids are present in admixture with a pharmaceutically acceptable carrier

Claim 13 adds adult patient + oral + daily dosage + a specific dose band:

• Oral
• daily dosage 1 to 10 g of the fatty acid mixture
• Active ingredients consist essentially of the EPA/DHA/HPA-defined mixture as above

Then the dependent claims tighten formulation and presentation:

• Claim 14: ≥85 wt% long chain omega-3.
• Claim 15: EPA 40-60 wt% and DHA 25-45 wt% (same as Claim 3 structure).
• Claim 16: EPA:DHA 1:1 to 2:1 (same as Claim 4 structure).
• Claim 17: other omega-3s with 20, 21, 22 carbons at ≥3 wt%.
• Claim 18: increases other C20-22 omega-3 threshold to ≥4.5 wt%.
• Claims 19-20: esterified form and ethyl ester.
• Claim 21: salt form.
• Claim 22: free acid form.

Cardiovascular claim scope by critical numeric gates

Where are the practical claim “pressure points” for freedom-to-operate?

1) The HPA requirement (≥1 wt%)

This is the most unusual limiter versus typical “EPA+DHA” patents. Many commercial omega-3 products target EPA and DHA, but do not market formulations with quantified heneicosapentaenoic acid at the ≥1 wt% level.

Implication: A product whose HPA content is below the threshold can avoid the literal composition definition, even if EPA and DHA match the ratio windows.

2) The EPA:DHA ratio windows (1:2 to 2:1; tighter 1:1 to 2:1)

Two layers matter:

• Claim 1/12/13: 1:2 to 2:1
• Certain dependent claims: 1:1 to 2:1

Implication: If a formulation falls outside these windows, it can be outside the dependent claims even if it fits the base.

3) “Consist essentially of” plus quantitative omega-3 gates

The phrase “active ingredients consist essentially of” combined with the numeric composition requirements can create a strong argument that the formulation must match the fatty acid profile as measured and quantified.

Implication: Substituting fatty acids (for example, using more shorter-chain omega-3s, other marine lipids, or different omega-3 lengths) could move the product outside the “consist essentially of” interpretation and also fail the quantified long-chain and C20-22 “other omega-3s” floors.

4) Ester form is a literal element in multiple dependent claims

The claims track ethyl ester, free acid, and salt. A product presented in a non-matching form might fall short of those dependent claims, though it may still fall within claims that do not specify form (unless “consist essentially of” and the esterified language indirectly constrain).

5) Therapeutic claim framing and indication strategy

There is a clean division:

• Hypertension (adult) daily treatment/prophylaxis
• Multiple cardiovascular risk factors in adults with daily dose range (for Claim 13)

Implication: Indication design matters. A formulation designed for hypertension may still face exposure if the product is used for that indication. A cardiovascular risk-factor indication may be harder to avoid if the dosing band overlaps.

What does this look like as a patent landscape node?

US 5,698,594 functions as a composition-defined omega-3 method-of-treatment patent with HPA-driven specificity and ratio- and profile-constrained fatty acid mixtures.

Claim set typology

• Type: Method of treatment/prophylaxis (not a composition product-by-itself claim in the excerpt)
• Ingredient definition: mixture-of-fatty-acids, “consist essentially of”
• Constrained actives: EPA + DHA + minimum HPA
• Route and dose elements: oral; daily 1-10 g in Claim 13
• Presentation options: esterified and specifically ethyl ester, plus salt and free acid

Competitive positioning (how other omega-3 patents typically compare)

In the broader omega-3 patent landscape, patents often fall into:

• “EPA/DHA ratio” constrained formulations (ratio-only)
• “omega-3 ethyl esters” for hypertriglyceridemia or dyslipidemia
• “treatment of cardiovascular outcomes” (indication-focused)
• **“composition with certain EPA and DHA amounts” but without requiring quantified HPA

US 5,698,594 is distinct because it requires quantified HPA at ≥1 wt%, which can be used as a design-around feature if experimentally confirmed.

Design-around map: where could an R&D team pivot?

A practical freedom-to-operate strategy would center on matching or breaking the claim numeric gates and presentation elements. Based on the claim text alone, the highest-leverage pivots are:

1. Quantify and control HPA content

   • Keep HPA below 1 wt% of the fatty acid mixture to target Claim 1/12/13-literal avoidance.

2. Shift EPA:DHA ratio outside windows

   • Move outside 1:2 to 2:1, or outside 1:1 to 2:1 for the narrower dependent claims.

3. Break long-chain or other C20-22 omega-3 floors

   • Avoid meeting the ≥85 wt% long chain omega-3 and/or the ≥3 wt% or ≥4.5 wt% other C20-22 omega-3 thresholds in the dependent claims.

4. Change fatty acid presentation

   • Use a form that does not align with dependent claims requiring ethyl ester, salt, or free acid where those elements are claimed.

5. Alter indication and dosing

   • For Claim 13 specifically, avoid the “multiple risk factors” framing with oral 1 to 10 g/day if that indication/dose pairing is a likely use case.

Risk assessment checklist tied to the literal claim elements

Independent claims to focus on

• Claim 1 (hypertension)
• Claim 12 (multiple cardiovascular risk factors)
• Claim 13 (adult + oral + 1-10 g/day for cardiovascular risk factors)

Litigation-sensitive elements

• EPA and DHA proportions: meet both total ≥80 wt% and ratio 1:2 to 2:1
• HPA ≥1 wt%
• Route (oral) in Claims 5 and 13
• Daily dose (1-10 g/day) in Claim 13
• Long-chain omega-3 ≥85 wt% and other omega-3 C20-22 thresholds in dependents

Key Takeaways

• US 5,698,594 is a method-of-treatment patent that ties hypertension and cardiovascular risk-factor prophylaxis to a highly specific omega-3 fatty acid mixture with quantified HPA (≥1 wt%), constrained EPA:DHA ratios, and additional long-chain/C20-22 omega-3 thresholds in dependent claims.
• The HPA requirement is the most distinctive scope gate and a key lever for formulation design-around if measured reliably.
• The landscape position is “ratio + profile + minor component + indication/dosing,” which is tighter than most EPA/DHA-only omega-3 patent families.
• Practical exposure hinges on formula analytics (HPA, EPA, DHA, other C20-22 omega-3s), dosage band (Claim 13), and the therapeutic use wording.

FAQs

1. Does US 5,698,594 cover any omega-3 composition with EPA and DHA?
   No. The claims require ≥80 wt% EPA+DHA plus ≥1 wt% HPA and specific EPA:DHA ratio windows.

2. Which claim introduces the daily dose band of 1 to 10 grams?
   Claim 13 for multiple cardiovascular risk factors in adults, with oral administration.

3. Is heneicosapentaenoic acid (HPA) optional?
   It is not optional in the independent claims. HPA is required at ≥1 wt% in Claims 1 and 12, and thus also in Claim 13.

4. Do the claims require ethyl ester presentation for all scope?
   No. Ethyl ester appears in multiple dependent claims (e.g., Claims 9, 11, 20). Independent claims do not mandate ethyl ester.

5. Can a product avoid dependent claims by changing ester form?
   Yes for those dependent claims that explicitly require ethyl ester, salt, or free acid. But the base composition and ratio/HPA elements can still control if the product matches the independent claim requirements.

References

[1] United States Patent No. 5,698,594. “Method for the treatment or prophylaxis of hypertension and multiple risk factors for cardiovascular disease using mixed fatty acids.” (Claims as provided).